Billing fraud investigation targets mental health hospitals

Five hospitals associated with a prominent Massachusetts mental health services provider are under investigation by the Department of Justice (DOJ) over accusations of billing fraud, according to a report in the Boston Globe.

The investigation, outlined in a report filed recently with the Securities and Exchange Commission, is targeting hospitals affiliated with Arbour Health System, which is owned by the largest psychiatric hospital and clinic provider in the U.S., Universal Health Services. 

Universal said the DOJ informed them of the investigation involving “billings submitted to government payers in relation to services provided at those facilities” in December of last year. A recent filing from the company reports that at least 25 of their member hospitals could potentially be investigated.

Universal’s chief financial officer Steve Filton recently told analysts that the company has “cooperated fully with the government and [has] responded to all their requests,” adding “This certainly has been long already. But I also do not believe that it is necessarily in its end stages.”

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.